Viewing Study NCT06868667

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:33 AM
Ignite Modification Date: 2026-02-13 @ 4:52 PM
Study NCT ID: NCT06868667
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-05-09
First Post: 2025-03-06
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Sponsor: GlaxoSmithKline
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Multiple Myeloma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Japan Expansion Cohort View
None Belantamab mafodotin View
None Relapsed/refractory multiple myeloma View
None Daratumumab View
None Bortezomib View
None Dexamethasone View
None Multiple Myeloma View